Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

ClinicalTrials.gov ID: NCT01575834

Public ClinicalTrials.gov record NCT01575834. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 5:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

Study identification

NCT ID
NCT01575834
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
7,180 participants

Conditions and interventions

Interventions

  • Denosumab Drug
  • Placebo Drug
  • Romosozumab Drug

Drug

Eligibility (public fields only)

Age range
55 Years to 90 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 14, 2012
Primary completion
Dec 13, 2015
Completion
Dec 27, 2016
Last update posted
Aug 27, 2024

2012 – 2016

United States locations

U.S. sites
25
U.S. states
17
U.S. cities
25
Facility City State ZIP Site status
Research Site Tucson Arizona 85704
Research Site Laguna Hills California 92653
Research Site Los Angeles California 90057
Research Site Sacramento California 95817
Research Site Santa Maria California 93454
Research Site Walnut Creek California 94598
Research Site Lakewood Colorado 80227
Research Site Leesburg Florida 34748
Research Site Palm Harbor Florida 34684
Research Site Plantation Florida 33324
Research Site Tampa Florida 33614
Research Site Gainesville Georgia 30501
Research Site New Orleans Louisiana 70121
Research Site Bethesda Maryland 20817
Research Site Boston Massachusetts 02114
Research Site Detroit Michigan 48236
Research Site Albuquerque New Mexico 87106
Research Site Asheville North Carolina 28803
Research Site Fargo North Dakota 58104
Research Site Cincinnati Ohio 45236
Research Site Mayfield Ohio 44143
Research Site Duncansville Pennsylvania 16635
Research Site Denton Texas 76210-8625
Research Site Richmond Virginia 23294
Research Site Madison Wisconsin 53705

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 193 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01575834, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 27, 2024 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01575834 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →